Translation

PATENT COOPERATION TREATY



PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference						
PCT-0406	FOR FURTHER ACTION		See Form PCT/IPEA/416			
International application No.	International filing de	ate (day/month/year)	Priority date (day/month/year)			
PCT/JP2004/007217	20 May 2004	(20.05.2004)	21 May 2003 (21.05.2003)			
International Patent Classification (IPC) or national classification and IPC C07D 401/12, 401/14, 405/12, 487/04, 487/10, A61K 31/506, 31/55, A61P 1/00, 15/06, 15/08, 17/00, 19/06, 25/00, 25/08, 25/20, 25/22, 25/24, 25/28, 25/30, 35/00, 43/00, 1/16, 3/04, 3/06, 3/10, 5/00, 9/00, 9/04, 9/10, 9/12, 11/00, 13/12, 15/00						
Applicant BANYU PHARMACEUTICAL CO., LTD.						
This report is the international prelin						
 This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 						
2. This REPORT consists of a total of4 sheets, including this cover sheet.						
3. This report is also accompanied by ANNEXES, comprising:						
a. (sent to the applicant and to the International Bureau) a total of sheets, as follows:						
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).						
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.						
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))						
readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).						
4. This report contains indications relati	ing to the following ite	ms:				
Box No. I Basis of the rep	port					
Box No. II Priority						
Box No. III Non-establishm	nent of opinion with re	gard to novelty, inventi-	ve step and industrial applicability			
Box No. IV Lack of unity of invention						
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
Box No. VI Certain documents cited						
Box No. VII Certain defects in the international application						
Box No. VIII Certain observations on the international application						
Date of submission of the demand		Date of completion of	this report			
07 December 2004 (07.12.2004)		29 M	29 March 2005 (29.03.2005)			
Name and mailing address of the IPEA/JP		Authorized officer				
Facsimile No.		Telephone No.				

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/JP2004/007217

Box No	. I	Basis of the report						
1. With other	regard	d to the language, this report is based on the international application in the language in which it was filed, unless						
	This which	report is based on translations from the original language into the following language, this language of a translation furnished for the purpose of:						
}	international search (under Rules 12.3 and 23.1(b))							
ļ	publication of the international application (under Rule 12.4)							
1		international preliminary examination (under Rules 55.2 and/or 55.3)						
		,						
	ire not	d to the elements of the international application, this report is based on (replacement sheets which have been to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" annexed to this report): International application as originally filed/furnished						
	the de	escription:						
	pages	, as originally filed/furnished						
	pages	* received by this Authority on						
	pages							
	the cla	aims;						
	pages	on minimally Classic and a						
	pages	, as originally filed/furnished , as amended (together with any statement) under Article 19						
	pages	received by this Authority on						
	pages							
	the dra	awings:						
d	pages							
	pages'	, as originally filed/furnished received by this Authority on						
	pages*							
	a semi							
<u> </u>	a boqu	ence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.						
3	The an	nendments have resulted in the cancellation of:						
		the description, pages						
		the claims, Nos.						
		the drawings, sheets/figs						
		the sequence listing (specify):						
		any table(s) related to sequence listing (specify):						
		(
	Rule 7	sport has been established as if (some of) the amendments annexed to this report and listed below had not been since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box the description, pages						
	H:	he description, pages						
	; ⊢	he claims, Nos.						
		he drawings, sheets/figs						
	⊣ "	he sequence listing (specify):						
İ	a	ny table(s) related to sequence listing (specify):						
If item	4 appli	ies, some or all of those sheets may be marked "superseded."						

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/JP2004/007217

Box No. V Reasoned states		under Article 25(2)	PC1/JP	PC1/JP2004/007217		
	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
1. Statement						
Novelty (N)	Claims	1-13				
		Claims	1-13	YES		
Inventive step (IS)				NO		
mventive step (15)	Claims	1-13	YES			
	Claims					
Industrial applicability (IA)		Claims		NO		
,,,,,,		1-13	YES			
	Claims		NO			
2. Citations as	nd explanations (Rule 7					
	~~ ovbrangrious (Kille)	J.7)				

Document 1: JP, 2002-3370, A (Takeda Chemical Industries, Ltd.), 09 January, 2002 Document 2: JP, 10-500960, A (Smithkline Beecham PLC), 27 January, 1998

The inventions relating to claims 1-13 are not disclosed in any of the documents cited in the ISR, and appear to be novel and to involve an inventive step. In particular, neither document 1 nor 2, which is found to be the most relevant prior art document, discloses the 2-aminoquinoline derivative represented by the general formula [1] and the salt that is pharmaceutically acceptable.